Insulet Corporation

Reporting payments is a legal requirement; large totals often reflect large product portfolios.

$10.0Mgeneral payments (2019-2025)
$15Kresearch payments (2019-2025)
17,340clinicians paid

General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.

General payments by year

2019 $2.1M
2020 $379K
2021 $1.1M
2022 $1.1M
2023 $1.1M
2024 $1.4M
2025 $2.9M

General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.

Products most associated with its payments

Specialties it works with most

Endocrinology, Diabetes & Metabolism $2.5M
Internal Medicine $2.0M
Family $1.3M
Surgical Oncology $832K
Pediatric Endocrinology $794K
Infectious Disease $672K

Clinicians with the largest reported totals

Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.

ClinicianLocationSpecialtyGeneral payments (2019-2025)
John Fallon Boston, MA Internal Medicine $1,678,547.01
Wayne Frederick Washington, DC Surgical Oncology $831,742.80
Luciana Borio Baltimore, MD Infectious Disease $671,150.76
Anita Swamy Chicago, IL Pediatric Endocrinology $339,370.00
Pablo Mora Dallas, TX Endocrinology, Diabetes & Metabolism $173,845.49
Marina Charitou East Setauket, NY Endocrinology, Diabetes & Metabolism $155,308.35
Eden Miller Bend, OR Family Medicine $147,500.27
Martin Sarkar Frederick, MD Endocrinology, Diabetes & Metabolism $147,386.01
Isaiah Pittman Terre Haute, IN Endocrinology, Diabetes & Metabolism $143,980.25
Ania Janicka Hudson, FL Endocrinology, Diabetes & Metabolism $138,418.64

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.